Literature DB >> 23494366

Secondary malignancy in patients with sporadic neuroendocrine neoplasia.

M Krausch1, A Raffel, M Anlauf, M Schott, N Lehwald, A Krieg, F Kröpil, K Cupisti, W T Knoefel.   

Abstract

The incidence of neuroendocrine neoplasias (NENs), especially of the gastro-entero-pancreatic (GEP), system relatively increased over the past decades, as a result of advanced diagnostic tools, a better clinical awareness, and distinguished pathological diagnostic recognition. Previous reports hypothesized an increased risk for secondary malignancies in patients with NEN especially in GEP-NENs. The present study was designed to investigate the coincidence of NENs and secondary malignancies in a large patient collective. A retrospective analysis was performed on 161 patients (85 female and 76 male) with NEN of various origins. Clinical data of these patients, different classification systems (TNM/WHO), proliferations-based grading, and clinical follow-up were collected and analyzed. Out of 143 patients with a sporadic NEN, 15 (10.49 %) patients were identified with secondary malignant tumors. Median age at the time of the primary operation for NEN was 65 years, whereas the median age of initial diagnosis of associated tumors was 59 years. Mean follow-up time was 61 months. The risk of developing a secondary malignancy was most elevated for patients with an NEN of the lung, the stomach, and the ileum (60, 50 and 20 %, respectively). The spectrum of secondary malignancies included various types of cancer. Kaplan-Meier survival analysis shows a difference suggesting that patients with a secondary malignancy demonstrate a worse survival compared to patients without a secondary tumor; no significance was detected (p = 0.349). Our data suggest that secondary malignancies in patients with NEN's especially in GEP-NENs are found more frequently than in general population. Therefore, patients with NEN need a continuous and detailed follow-up. The reason for the increased incidence of secondary malignancies in patients with NENs remains to be elucidated.

Entities:  

Mesh:

Year:  2013        PMID: 23494366     DOI: 10.1007/s12020-013-9911-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  53 in total

1.  Risk of second malignant neoplasm following proton versus intensity-modulated photon radiotherapies for hepatocellular carcinoma.

Authors:  Phillip J Taddei; Rebecca M Howell; Sunil Krishnan; Sarah B Scarboro; Dragan Mirkovic; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

2.  An analysis of 8305 cases of carcinoid tumors.

Authors:  I M Modlin; A Sandor
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

Review 3.  Gastrin as a growth factor in the gastrointestinal tract.

Authors:  T J Koh; D Chen
Journal:  Regul Pept       Date:  2000-09-25

4.  Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells.

Authors:  Giovanni Vitale; Peter M van Koetsveld; Wouter W de Herder; Katy van der Wansem; Joop A M J L Janssen; Annamaria Colao; Gaetano Lombardi; Steven W J Lamberts; Leo J Hofland
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-01-13       Impact factor: 4.310

5.  Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system.

Authors:  A Chaudhry; K Oberg; A Gobl; C H Heldin; K Funa
Journal:  Anticancer Res       Date:  1994 Sep-Oct       Impact factor: 2.480

6.  Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.

Authors:  Jonathan Strosberg; Aejaz Nasir; Domenico Coppola; Mark Wick; Larry Kvols
Journal:  Hum Pathol       Date:  2009-04-14       Impact factor: 3.466

Review 7.  Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.

Authors:  Günter Klöppel; Guido Rindi; Martin Anlauf; Aurel Perren; Paul Komminoth
Journal:  Virchows Arch       Date:  2007-08-08       Impact factor: 4.064

8.  Gastrin stimulates growth of human colon cancer cells via a receptor other than CCK-A or CCK-B.

Authors:  R J Bold; J Ishizuka; C M Townsend; J C Thompson
Journal:  Biochem Biophys Res Commun       Date:  1994-08-15       Impact factor: 3.575

9.  Gastrin and colorectal cancer: a prospective study.

Authors:  C M Thorburn; G D Friedman; C J Dickinson; J H Vogelman; N Orentreich; J Parsonnet
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

10.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

View more
  2 in total

1.  Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective.

Authors:  Giovanna Muscogiuri; Barbara Altieri; Manuela Albertelli; Andrea Dotto; Roberta Modica; Luigi Barrea; Giuseppe Fanciulli; Tiziana Feola; Roberto Baldelli; Rosaria Maddalena Ruggeri; Marco Gallo; Valentina Guarnotta; Pasqualino Malandrino; Erika Messina; Mary Anna Venneri; Elisa Giannetta; Diego Ferone; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2020-05-28       Impact factor: 3.633

2.  Second cancers in patients with neuroendocrine tumors.

Authors:  Hui-Jen Tsai; Chun-Chieh Wu; Chia-Rung Tsai; Sheng-Fung Lin; Li-Tzong Chen; Jeffrey S Chang
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.